INTRODUCTION
============

Alcohol is an important cause of chronic liver disease. Chronic alcohol intake aggravates most liver diseases, and moderate alcohol intake may exacerbate certain liver diseases. For example, moderate alcohol consumption (60 g/day for men and 40 g/day for women) in patients with hepatitis B virus infection increased the incidence of hepatocellular carcinoma (HCC) by about 1.5-fold,[@b1-gnl-13-308]--[@b4-gnl-13-308] although the cutoff values of alcohol intake were unclear.[@b4-gnl-13-308]

However, effects of moderate alcohol consumption in specific liver diseases are still in debate. For example, many studies examined the effects of moderate alcohol consumption in the prevalence of nonalcoholic fatty liver disease (NAFLD). In a study by Sogabe *et al*.,[@b5-gnl-13-308] moderate alcohol drinking of ≤140 g/wk was associated with lower prevalence of NAFLD in Japanese females. In contrast, a study by Liu *et al*.[@b6-gnl-13-308] suggested moderate alcohol drinking was associated with higher prevalence of NAFLD in Chinese men. Roerecke *et al*.[@b7-gnl-13-308] reviewed that moderate alcohol drinking was associated with lower prevalence of NAFLD in Japanese, but not in other countries.

Interestingly, there were some researches suggesting that nonalcoholic steatohepatitis (NASH) and liver fibrosis were negatively associated with moderate alcohol consumption in patients with NAFLD, although NAFLD is similar to alcoholic fatty liver disease and has a similar pathological physiology.[@b8-gnl-13-308] Previously, effects of moderate alcohol drinking in NAFLD patients were reviewed by Ajmera *et al*.[@b9-gnl-13-308] and Boyle *et al*.[@b10-gnl-13-308] However, the effects were not summarized by specific clinical symptoms. In this review, we compared and analyzed studies investigating the effects of moderate alcohol drinking on NASH and fibrosis in patients with NAFLD.

OVERVIEW OF THE EFFECT OF ALCOHOL ON NAFLD
==========================================

To date, 11 studies were available on the effects of alcohol on liver disease progression in patients with NAFLD ([Table 1](#t1-gnl-13-308){ref-type="table"}).[@b8-gnl-13-308],[@b11-gnl-13-308]--[@b20-gnl-13-308] Four were cohort studies, and seven were cross-sectional studies. One cohort study suggested a negative correlation between moderate alcohol drinking and fibrosis,[@b13-gnl-13-308] while another cohort study suggested no correlation.[@b12-gnl-13-308] The longitudinal cohort study suggested less improvement of NAFLD in the consistent moderate alcohol drinking group.[@b18-gnl-13-308] The other cohort study suggested even moderate alcohol drinking may exacerbate HCC development. [@b17-gnl-13-308]

Three cross-sectional studies suggested that moderate alcohol drinking was negatively associated with the prevalence of NASH and advanced hepatic fibrosis.[@b8-gnl-13-308],[@b11-gnl-13-308],[@b19-gnl-13-308] However, four cross-sectional studies suggested that moderate alcohol drinking was not associated with NASH progression and fibrosis deterioration. [@b14-gnl-13-308]--[@b16-gnl-13-308]

METHOD OF ASSESSING ALCOHOL CONSUMPTION
=======================================

Each study used various methods to analyze the alcohol intake of patients ([Table 2](#t2-gnl-13-308){ref-type="table"}). Eight studies obtained alcohol intake data through the self-reports of patients,[@b8-gnl-13-308],[@b11-gnl-13-308]--[@b13-gnl-13-308],[@b16-gnl-13-308],[@b18-gnl-13-308]--[@b20-gnl-13-308] and four studies interviewed patients through experts.[@b11-gnl-13-308],[@b12-gnl-13-308],[@b14-gnl-13-308],[@b16-gnl-13-308] Two studies used both the self-report method and the interview method.[@b12-gnl-13-308],[@b16-gnl-13-308] One study was unclear how alcohol consumption was analyzed. [@b17-gnl-13-308]

In most studies, alcohol intake was measured at a specific time point. Two studies used the alcohol use disorder identification test (AUDIT) or AUDIT -- consumption (AUDIT-C) questionnaires. [@b8-gnl-13-308],[@b12-gnl-13-308],[@b18-gnl-13-308],[@b20-gnl-13-308] However, AUDIT is intended to identify persons with hazardous and harmful patterns of alcohol consumption.[@b21-gnl-13-308] This questionnaire consists of 10 questions, of which questions 1 to 3 are direct questions about the amount of alcohol consumption. AUDIT-C is a questionnaire that includes only these three questions. Therefore, AUDIT and AUDIT-C have limitations in accurately analyzing the amount or pattern of alcohol consumption. Only four studies included the lifetime drinking history of patients.[@b8-gnl-13-308],[@b11-gnl-13-308],[@b13-gnl-13-308],[@b18-gnl-13-308] A lifetime drinking history questionnaire was designed to record all alcohol consumptions up to the time the patient was asked. The items listed included drinking duration, a frequency of drinking, intake per serving, and type of alcohol.[@b22-gnl-13-308] Including the lifetime drinking history is important because past drinking behavior can alter the patients' current health status.

WHAT IS "MODERATE" ALCOHOL CONSUMPTION?
=======================================

The definitions of moderate alcohol consumption were different in each article ([Fig. 1](#f1-gnl-13-308){ref-type="fig"}). The lowest cutoff was 40 g/wk, and the highest was 308 g/wk. The mean was 167 g/wk. Excluding the outlying lowest cutoff value of Kwon *et al*.,[@b11-gnl-13-308] the mean was 180 g/wk. The cutoff value for moderate alcohol consumption in most articles ranged between 140 and 200 g/wk. This is similar to the cutoffs of 210 g/wk for men and 140 g/wk for women that distinguish between alcoholic steatohepatitis and NASH.[@b23-gnl-13-308]

EFFECTS OF MODERATE ALCOHOL CONSUMPTION ON LIVER FIBROSIS IN NAFLD
==================================================================

Eight studies showed the relationship between moderate alcohol intake and the degree of fibrosis ([Table 3](#t3-gnl-13-308){ref-type="table"}).[@b8-gnl-13-308],[@b11-gnl-13-308]--[@b13-gnl-13-308],[@b15-gnl-13-308],[@b16-gnl-13-308],[@b18-gnl-13-308],[@b20-gnl-13-308] Scoring system used to assess the degree of intrahepatic fibrosis were various. Five studies used the NASH Clinical Research Network scoring system for assessing the progression of NASH. Among them, four studies suggested that the level of liver fibrosis was low in patients with moderate alcohol consumption (p≤0.05),[@b8-gnl-13-308],[@b11-gnl-13-308],[@b13-gnl-13-308],[@b19-gnl-13-308] while the other study showed no correlation.[@b18-gnl-13-308]

Other three studies used different scoring systems. One study[@b12-gnl-13-308] used the Brunt system to evaluate the degree of NAFLD.[@b24-gnl-13-308] Another study[@b15-gnl-13-308] used NAFLD fibrosis scores without biopsy to evaluate the degree of liver fibrosis.[@b25-gnl-13-308] The other study[@b20-gnl-13-308] used controlled attenuation parameter method to evaluate the degree of liver fibrosis. The three studies showed that moderate alcohol intake and fibrosis severity were not associated.[@b12-gnl-13-308],[@b15-gnl-13-308]

Above finding changed after subgroup analysis according to types of study design. Among the eight studies, five were cross-sectional studies.[@b8-gnl-13-308],[@b11-gnl-13-308],[@b15-gnl-13-308],[@b19-gnl-13-308] Three of them showed the negative association between liver fibrosis and moderate alcohol consumption. [@b8-gnl-13-308],[@b11-gnl-13-308],[@b19-gnl-13-308] Only one study among the three cohort studies showed the negative association between liver fibrosis and moderate alcohol consumption.[@b12-gnl-13-308],[@b13-gnl-13-308],[@b18-gnl-13-308]

Interestingly, above finding was related to methods of assessing alcohol consumption. Most studies that evaluated lifetime drinking history suggested a negative association between liver fibrosis and moderate alcohol consumption,[@b8-gnl-13-308],[@b11-gnl-13-308],[@b13-gnl-13-308],[@b19-gnl-13-308] except for one study.[@b18-gnl-13-308]

EFFECTS OF MODERATE ALCOHOL CONSUMPTION ON THE PRESENCE OF NASH
===============================================================

Four studies suggested the effects of moderate alcohol intake on the incidence of intrahepatic inflammation in patients with NAFLD,[@b8-gnl-13-308],[@b13-gnl-13-308],[@b16-gnl-13-308],[@b18-gnl-13-308] however, the results were diverse ([Table 4](#t4-gnl-13-308){ref-type="table"}). Alcohol consumption of \<20 g/day was negatively associated with the incidence of NASH (p=0.0006) in a study by Dunn *et al*.[@b8-gnl-13-308] However, in a study by Hagström *et al*.,[@b13-gnl-13-308] moderate alcohol consumption was not associated with the incidence of NASH. Dixon *et al*.[@b16-gnl-13-308] reported that moderate alcohol intake was negatively associated with the incidence of NASH in patients with high obesity. Nevertheless, there was no association between alcohol consumption and the incidence of NASH after adjusting for diabetes or insulin resistance. In a study by Ajmera *et al*.,[@b18-gnl-13-308] moderate alcohol drinking was associated with less prevalence of NASH at the baseline. However, after 4 years, consistent moderate drinkers showed less resolution of definite NASH than consistent nondrinkers.

EFFECTS OF MODERATE ALCOHOL CONSUMPTION ON AMINOTRANSFERASE ACTIVITY IN NAFLD
=============================================================================

Seven articles suggested the relationship between alcohol consumption and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels.[@b11-gnl-13-308],[@b13-gnl-13-308]--[@b15-gnl-13-308],[@b18-gnl-13-308]--[@b20-gnl-13-308] The AST levels were not different between moderate drinkers and nondrinkers in all seven studies ([Table 5](#t5-gnl-13-308){ref-type="table"}). While there was no difference of ALT levels between the two groups in most studies, ALT levels were lower in patients consuming \<20 g/day of alcohol than in nondrinkers in one study. This study also suggested that ALT and AST levels were higher in patients consuming 20--40 g/day of alcohol.[@b14-gnl-13-308]

EFFECTS OF MODERATE ALCOHOL CONSUMPTION ON BIOCHEMICAL PARAMETERS AND CARDIOVASCULAR DISEASE IN NAFLD
=====================================================================================================

The effect of moderate alcohol intake on cholesterol levels in patients with NAFLD was controversial in the three studies ([Supplementary Table 1](#s1-gnl-13-308){ref-type="supplementary-material"}).[@b11-gnl-13-308],[@b13-gnl-13-308],[@b19-gnl-13-308] The triglyceride levels were not significantly different between alcohol drinkers and nondrinkers in the four studies (p\>0.05).[@b8-gnl-13-308],[@b11-gnl-13-308],[@b18-gnl-13-308],[@b19-gnl-13-308] In general, there was no significant difference of high-density lipoprotein (HDL) and homeostasis model assessment of insulin resistance (HOMA-IR) between the two groups.[@b11-gnl-13-308],[@b13-gnl-13-308]--[@b15-gnl-13-308],[@b18-gnl-13-308],[@b19-gnl-13-308]

Two studies suggested the relationship between moderate alcohol intake and hypertension in patients with NAFLD ([Supplementary Table 2](#s1-gnl-13-308){ref-type="supplementary-material"}). In one study, the incidence of hypertension in the moderate alcohol user group was lower than that in the nondrinking group,[@b13-gnl-13-308] while the other study suggested a lower incidence of hypertension in the 20--40 g/day alcohol consumption group than in the nondrinking group.[@b14-gnl-13-308] In the study by Sinn *et al*.,[@b15-gnl-13-308] the prevalence of carotid plaques and carotid stenosis were lower in patients with moderate alcohol intake.

DISCUSSION
==========

In conclusion, moderate alcohol intake in patients with NAFLD has varied results. However, moderate alcohol intake is associated with a low incidence of intrahepatic fibrosis and NASH despite variety and uncertainty on methods of assessing alcohol consumption.

Several studies demonstrated possible mechanisms for beneficial effects of moderate alcohol consumption. In the animal study by Kanuri *et al*.,[@b26-gnl-13-308] moderate alcohol drinking was associated with lower inflammation in liver. The hepatoprotective property was associated with an induction of the sirtuin-1/adiponectin-signaling cascade in visceral fat tissue and activation of protein kinase B in the liver. Wang and his coworkers found that moderate alcohol intake induces thermogenic brown/beige adipocyte formation and promotes glucose and lipid oxidation via elevating retinoic acid signaling.[@b27-gnl-13-308] This resulted in the prevention of high-fat-diet-induced obesity and metabolic dysfunction. Yamada *et al*.[@b19-gnl-13-308] evaluated the effects of light alcohol consumption on gene expression in the liver. The moderate alcohol drinking was associated with lowered expression of Toll-like receptor 4, nuclear factor-kappa beta and more genes which are involved in immune response pathways.

Yet, it may be early to recommend drinking to patients with NAFLD. Firstly, there were no randomized control trials and all studies were cross-sectional studies or cohort studies. Secondly, the effect of alcohol intake on liver cancer in patients with NAFLD is controversial. Among the 11 journals we reviewed, only one journal analyzed the effect of moderate alcohol drinking on the risk of HCC.[@b17-gnl-13-308] The study used 308 g/wk as a cutoff value for the definition of moderate alcohol drinking. This is a much higher value compared to other journals we reviewed since the average was 167 g/wk. More clinical data is needed to further analyze the effect of moderate alcohol drinking on HCC development in the patient with NAFLD. Thirdly, the methods used for assessing alcohol consumption have many limitations. Fourthly, the longitudinal cohort study suggested that the modest alcohol use is associated with less improvement of NASH.[@b18-gnl-13-308] Lastly, the amount of moderate alcohol consumption defined in each article was different. Clinical data are still lacking, and the conclusion cannot be drawn on how much alcohol is appropriate for each individual patient. Additional studies should be undertaken on the analysis of adequate alcohol intake, patterns of intake, and positive and negative effects.
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###### 

Alcohol Consumption and Severity of Liver Disease in NAFLD

  Author (year)                               Study population                   Study design           Sample size                               Definition of moderate alcohol use   Method for determining NAFLD       Outcome measure                                            Conclusion
  ------------------------------------------- ---------------------------------- ---------------------- ----------------------------------------- ------------------------------------ ---------------------------------- ---------------------------------------------------------- ------------------------------------------------------------------------------------------
  Kwon *et al*. (2014)[@b11-gnl-13-308]       USA, NAFLD                         Cross-sectional        77 (43 female)                            ≤40 g/wk                             Liver biopsy                       Fibrosis stage, fibrosis score, ALT, AST, fibrosis score   Lower fibrosis score in the above-median alcohol consumption group
  Dunn *et al*. (2012)[@b8-gnl-13-308]        USA, NAFLD                         Cross-sectional        582 (384 female)                          ≤140 g/wk                            Liver biopsy                       Fibrosis stage, steatohepatitis state                      Lower risk for fibrosis and steatohepatitis in moderate alcohol consumption group
  Ekstedt *et al*. (2009)[@b12-gnl-13-308]    Scandinavia, NAFLD                 Prospective cohort     71 (20 female)                            ≤140 g/wk                            Liver biopsy                       Fibrosis stage, ALT, AST                                   Heavy episodic drinking positively relates with higher fibrosis stage
  Hagström *et al*. (2017)[@b13-gnl-13-308]   Sweden, NAFLD                      Prospective cohort     120 (37 female)                           ≤168 g/wk                            Liver biopsy                       Fibrosis stage, ALT, AST                                   Moderate alcohol consumption and fibrosis stage relates negatively
  Cotrim *et al*. (2009)[@b14-gnl-13-308]     Brazil, obese (BMI \>40 kg/m^2^)   Cross-sectional        132 (91 female)                           ≤280 g/wk                            Liver biopsy                       Fibrosis stage, ALT, AST, IR                               Alcohol and NAFLD severity had no correlation
  Sinn *et al*. (2014)[@b15-gnl-13-308]       Korea, NAFLD                       Cross-sectional        2280 (male only)                          ≤140 g/wk                            Ultrasound                         Fibrosis score, ALT, AST, carotid plaque                   Moderate alcohol consumption and carotid plaques formation relates negatively
  Dixon *et al*. (2001)[@b16-gnl-13-308]      Australia, obese                   Cross-sectional        105 (23 female)                           ≤200 g/wk                            Liver biopsy                       ALT, AST                                                   Less NASH probability in the moderate alcohol drinking group
  Ascha *et al*. (2010)[@b17-gnl-13-308]      USA                                Retrospective cohort   510 (183 female), NASH 195 (109 female)   ≤308 g/wk                            Liver biopsy                       HCC development                                            Alcohol consumption positively relates with risk of HCC
  Ajmera *et al*. (2018)[@b18-gnl-13-308]     NASH-CRN participants              Longitudinal cohort    285 (199 female)                          ≤140 g/wk                            Liver biopsy                       Resolution of definit NASH, Fibrosis score, ALT, AST       Less improvement of NAFLD in the consistent moderate alcohol drinking group
  Yamada *et al*. (2018)[@b19-gnl-13-308]     Japanese, NAFLD                    Cross-sectional        178 (85 female)                           ≤140 g/wk                            Liver biopsy                       Fibrosis score, steatosis score                            Less fibrosis score in the moderate alcohol drinking group
  Patel *et al*. (2017)[@b20-gnl-13-308]      Australian, diabetes and NAFLD     Cross-sectional        151 (55 female)                           ≤140 g/wk                            Controlled attenuation parameter   Liver stiffness, ALT, AST                                  Alcohol consumption is not associated with lifer fibrosis in diabetic and NAFLD patients

NAFLD, nonalcoholic fatty liver disease; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; IR, insulin resistance; NASH, nonalcoholic steatohepatitis; HCC, hepatocellular carcinoma; NASH-CRN, Nonalcoholic Steatohepatitis Clinical Research Network.

###### 

Method of Assessing Alcohol Consumption

  Author (year)                               Self-report/interview   Interview   Including life-time drinking patterns   Types of food frequency questionnaire
  ------------------------------------------- ----------------------- ----------- --------------------------------------- --------------------------------------------------------------
  Kwon *et al*. (2014)[@b11-gnl-13-308]                               O           O                                       Skinner Lifetime Drinking History interview
  Dunn *et al*. (2012)[@b8-gnl-13-308]        O                                   O                                       Skinner Lifetime Drinking History and AUDIT questionnaires
  Ekstedt *et al*. (2009)[@b12-gnl-13-308]    O                       O                                                   AUDIT-C questionnaire
  Hagström *et al*. (2017)[@b13-gnl-13-308]   O                                   O                                       Skinner Lifetime Drinking History questionnaire
  Cotrim *et al*. (2009)[@b14-gnl-13-308]                             O                                                   \-
  Sinn *et al*. (2014)[@b15-gnl-13-308]       O                                                                           \-
  Dixon *et al*. (2001)[@b16-gnl-13-308]      O                       O                                                   \-
  Ascha *et al*. (2010)[@b17-gnl-13-308]                                                                                  Not clearly stated
  Ajmera *et al*. (2018)[@b18-gnl-13-308]     O                                   O                                       Skinner Lifetime Drinking History and AUDIT-C questionnaires
  Yamada *et al*. (2018)[@b19-gnl-13-308]     O                                                                           \-
  Patel *et al*. (2017)[@b20-gnl-13-308]      O                                   O                                       AUDIT questionnaires

AUDIT, alcohol use disorder identification test; AUDIT-C, alcohol use disorder identification test-consumption.

###### 

Effects of Moderate Alcohol Drinking on Liver Fibrosis

  Author (year)                               Fibrosis   Remarks
  ------------------------------------------- ---------- ---------------------------------------------------------------------------------------------------------------------------------------------------------
  Kwon *et al*. (2014)[@b11-gnl-13-308]       ↓          Fibrosis score (1.2±1.0 vs 1.8±1.2, p=0.03) among the above-median alcohol consumption versus below-median alcohol consumption groups
  Dunn *et al*. (2012)[@b8-gnl-13-308]        ↓          Higher fibrosis stage: OR, 0.56 (95% CI, 0.41--0.78; p=0.0005) among moderate alcohol users versus lifelong nondrinkers
  Ekstedt *et al*. (2009)[@b12-gnl-13-308]    \-         Fibrosis progression: OR, 1.012 (95% CI, 1.000--1.025; p=0.055) among alcohol users versus nondrinkers
  Hagström *et al*. (2017)[@b13-gnl-13-308]   ↓          Higher fibrosis stage: OR, 0.86 (95% CI, 0.77--0.97; p=0.016) among the above-median alcohol consumption versus below-median alcohol consumption groups
  Sinn *et al*. (2014)[@b15-gnl-13-308]       \-         Fibrosis score (−1.9 vs −1.9; p=0.93) among moderate alcohol drinkers versus nondrinkers
  Ajmera *et al*. (2018)[@b18-gnl-13-308]     \-         Change in fibrosis score (0.08±0.16 vs 0.06±0.18; p=0.85) among moderate alcohol drinkers versus nondrinkers
  Yamada *et al*. (2018)[@b19-gnl-13-308]     ↓          Fibrosis score: OR, 0.707 (95% CI, 0.512--0.977; p=0.035) among moderate alcohol users versus lifelong nondrinkers
  Patel *et al*. (2017)[@b20-gnl-13-308]      \-         Liver stiffness measurement over 0.82 kPa: OR, 0.91 (95% CI, 0.27--3.10; p=0.881) among moderate alcohol users versus lifelong nondrinkers

OR, odds ratio; CI, confidence interval.

###### 

Effects of Moderate Alcohol Drinking on NASH

  Author (year)                               NASH   Remarks
  ------------------------------------------- ------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Dunn *et al*. (2012)[@b8-gnl-13-308]        ↓      NASH: OR, 0.52 (95% CI, 0.36--0.76; p=0.0006) among moderate alcohol users versus lifelong non-drinkers
  Hagström *et al*. (2017)[@b13-gnl-13-308]   \-     NASH: OR, 0.98 (95% CI, 0.86--1.11; p=0.71) among the above-median alcohol consumption versus below-median alcohol consumption groups
  Dixon *et al*. (2001)[@b16-gnl-13-308]      ↓      NASH: OR, 0.35 (95% CI, 0.12--1.0; p=0.040) among moderate alcohol users versus lifelong non-drinkers before adjusting for diabetes or insulin resistance
                                              \-     NASH after adjusting for diabetes or insulin resistance
  Ajmera *et al*. (2018)[@b18-gnl-13-308]     ↓      Definite NASH prevalence at the baseline (57% vs 74%, p=0.01) among moderate alcohol users versus lifelong nondrinkers
                                              ↑      Resolution of definite NASH after 4 years: difference in adjusted mean change, 0.32 (95% CI, 0.11--0.92; p=0.04) among consistent moderate drinkers and consistent nondrinkers

NASH, nonalcoholic steatohepatitis; OR, odds ratio; CI, confidence interval.

###### 

Effects of Moderate Alcohol Drinking on ALT/AST

  Author (year)                               ALT   Conclusion, IU/L                                                                                                    AST   Conclusion, IU/L
  ------------------------------------------- ----- ------------------------------------------------------------------------------------------------------------------- ----- -------------------------------------
  Kwon *et al*. (2014)[@b11-gnl-13-308]       \-    78±37 vs 73±59, p=0.68; among the above-median alcohol consumption versus below-median alcohol consumption groups   \-    50±24 vs 56±43, p=0.44
  Hagström *et al*. (2017)[@b13-gnl-13-308]   \-    61 vs 55, p=0.22; among moderate alcohol drinkers versus below-median drinkers                                      \-    44 vs 44, p=0.76
  Cotrim *et al*. (2009)[@b14-gnl-13-308]     ↓     48 vs 30 vs 35; among G1 (20--40 g/day) vs G2 (0--20 g/day) vs G3 (nondrinkers)                                     \-    30 vs 23 vs 24
  Sinn *et al*. (2014)[@b15-gnl-13-308]       \-    29 vs 28, p=0.11; among moderate alcohol drinkers versus nondrinkers                                                \-    24 vs 24, p=0.85
  Ajmera *et al*. (2018)[@b18-gnl-13-308]     \-    62 vs 57, p=0.08; among moderate alcohol drinkers versus nondrinkers                                                \-    43 vs 42, p=0.37
  Yamada *et al*. (2018)[@b19-gnl-13-308]     \-    68.5±49.8 vs 64.1±79.8, p=0.0610; among moderate alcohol drinkers versus nondrinkers                                \-    40.1±22.9 vs 46.1±42.6, p=0.6993
  Patel *et al*. (2017)[@b20-gnl-13-308]      \-    36.4±26.4 vs 38.4±29.5 vs 37.4±15.8; among nondrinkers versus light drinkers versus moderate drinkers               \-    29.0±17.6 vs 28.6±26.1 vs 24.7±11.2

ALT, alanine aminotransferase; AST, aspartate aminotransferase.
